68Ga-NYM096 PET/CT imaging in different cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center imaging study in which each participant receives a single intravenous dose of 68Ga-NYM096 followed by dedicated whole-body PET/CT. Scans are performed when referring physicians consider standard 18F-FDG PET/CT or other imaging insufficient. Quantitative image analyses will measure lesion number, SUVmax (40% isocontour), and tumor-to-background ratios across primary and metastatic sites. Up to 120 patients with histologically proven tumors or unequivocal metastases will be enrolled to define tumor uptake patterns and identify promising indications for future use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 y
2. Histopathologically confirmed cancer (histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors)
3. Expected survival of at least 3 months
4. ECOG ≤ 2
5. Written informed consent provided for participation in the trial
6. In the opinion of investigator, willing and able to comply with required study procedures.

Exclusion Criteria:

1. On VEGF TKI treatment less than 1 week before 68Ga-NYM096 PET/CT. TKI is known to affect girentuximab binding in patients with ccRCC and is expected to have the same effect on 68Ga-NYM096. If patients were on VEGF TKI treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NYM096 PET/CT is required.
2. Intercurrent medical condition that renders the patient ineligible for the procedures.
3. Pregnancy or breastfeeding.
4. Severe claustrophobia.

Where it's running

• Peking Union Medical College Hospital, Beijing, Beijing 100730
  Beijing, China Recruiting

Study contacts

• Study coordinator: Li Huo, MD
• Email: huoli@pumch.cn
• Phone: +86 18612672038

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Glycogen Storage Disease and Brain Function in People Like You

  This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07908212

• FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy

  This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07878338

• Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer

  This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07854600

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

• Lenvatinib plus chemotherapy for pancreatic neuroendocrine tumors with liver metastases

  This study tests whether adding lenvatinib to chemotherapy helps people with pancreatic neuroendocrine tumors that have spread to the liver, after first-line therapy has stopped working.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07835893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.